Institutional Sourcing Network

The intelligence layer for global biotech sourcing.

Biotech Buyer connects manufacturers, pharmaceutical suppliers, laboratories, and institutional buyers through a curated network built on data, diligence, and discretion.

ISO 27001SOC 2 Type IIGDPR · HIPAA42 jurisdictions
01Trusted by the world's most discerning operators
AETHER BIO
MERIDIAN PHARMA
NORTHWIND LABS
HALCYON THERAPEUTICS
VANTAGE GENOMICS
OBSIDIAN CAPITAL
Sourced volume across the network$4.8BTrailing twelve months
Vetted institutional buyers1,240+Across 42 jurisdictions
Average sourcing cycle11 daysFrom mandate to introductions
Credential verification rate100%Manual diligence on every entrant
02Capabilities

Sourcing as an
institutional discipline.

Our network is engineered for participants who require precision, discretion, and scale. Each capability is delivered by senior practitioners and supported by a verified data layer.

C.01

Manufacturer sourcing

Identify pre-vetted biotech and pharmaceutical manufacturers across cell therapy, biologics, and small-molecule production with verified capacity and regulatory standing.

  • FDA, EMA, PMDA credentialing
  • GMP capacity intelligence
  • Quality, scale, and IP diligence
C.02

Buyer acquisition

Curated introductions to institutional buyers — strategic acquirers, healthcare investors, sovereign funds, and global procurement teams operating with mandate and capital.

  • Mandate-matched introductions
  • Confidential outreach protocols
  • Stage-aligned investor mapping
C.03

Market intelligence

Continuous, structured intelligence on supply, demand, and pricing across regulated life sciences markets — informed by primary research and verified counterparties.

  • Supply and demand telemetry
  • Regulatory horizon scanning
  • Comparable transaction data
C.04

Transaction advisory

Senior advisory through diligence, structuring, and close — with discretion appropriate to cross-border life sciences transactions and institutional standards.

  • Diligence orchestration
  • Structuring and negotiation support
  • Cross-border legal coordination
03The buyer network

Capital and intent,
introduced with discretion.

Every counterparty is verified on standing, mandate, and capital before introduction. We do not list. We curate, qualify, and place — engagement by engagement.

Strategic acquirers180+Top 50 global pharma and medtech
Healthcare investors420+Growth, buyout, and life-sciences specialist funds
Sovereign and family capital85+Long-duration mandates with strategic intent
Institutional procurement560+Health systems, laboratories, and government buyers
Live network telemetry
UTC · realtime
  • EMEAStrategic acquirer
    Engaged
  • APACSovereign fund
    Reviewing
  • AmericasSpecialty growth fund
    Introduced
  • EMEAHealth-system procurement
    Sourcing
Showing 4 of 1,240 active counterpartiesEnd-to-end encrypted
04Global reach

A network with
planetary coverage.

Senior practitioners across four regions operate under a single mandate: surface and qualify the most relevant counterparties for each engagement, anywhere in the world.

North AmericaBoston · San Francisco · New York · Toronto420
EuropeLondon · Basel · Copenhagen · Munich380
Asia PacificSingapore · Tokyo · Seoul · Sydney260
Middle East · Latin AmericaDubai · Riyadh · São Paulo · Mexico City180
Active engagement nodes
05Standards

Trust is engineered,
not implied.

"Biotech Buyer surfaced counterparties our internal team had not seen in eighteen months of mandate development. The diligence was institution-grade."

Managing DirectorEuropean healthcare buyout fund

"We treat their introductions the way we treat introductions from the most senior banks. Considered, qualified, and worth the room."

Head of StrategyTop-20 global pharmaceutical company

"Discreet, precise, and globally fluent. They understand that our reputation travels with every introduction."

Chief Investment OfficerSovereign life-sciences platform
Verified counterparties

Every entrant is manually credentialed against regulatory standing, capital, and mandate.

Confidential by design

Engagements operate under NDA, with controlled disclosure and end-to-end encrypted exchange.

Senior-only practice

Engagements are led by partners with operating histories at global pharma, regulators, and capital allocators.

06Engagement

Begin a confidential conversation.

Engagements are accepted by referral and selective inbound. Share your mandate and a senior partner will respond within one business day.